We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00943488
First Posted: July 22, 2009
Last Update Posted: October 31, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
Results First Submitted: March 10, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were healthy adult males and females recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 07AUG2009 and 21AUG2009

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
H1N1 Vaccine 15 Mcg Participants received 15 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.
H1N1 Vaccine 30 Mcg Participants received 30 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.

Participant Flow:   Overall Study
    H1N1 Vaccine 15 Mcg   H1N1 Vaccine 30 Mcg
STARTED   204   204 
COMPLETED   203   202 
NOT COMPLETED   1   2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
H1N1 Vaccine 15 Mcg Participants received 15 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.
H1N1 Vaccine 30 Mcg Participants received 30 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.
Total Total of all reporting groups

Baseline Measures
   H1N1 Vaccine 15 Mcg   H1N1 Vaccine 30 Mcg   Total 
Overall Participants Analyzed 
[Units: Participants]
 204   204   408 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   102   98   200 
>=65 years   102   106   208 
Age 
[Units: Years]
Mean (Standard Deviation)
 57.9  (17.1)   59.5  (15.9)   58.7  (16.5) 
Gender 
[Units: Participants]
     
Female   105   114   219 
Male   99   90   189 
Region of Enrollment 
[Units: Participants]
     
United States   204   204   408 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the First Vaccination   [ Time Frame: Day 0-7 after first vaccination ]

2.  Primary:   Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the Second Vaccination   [ Time Frame: Day 0-7 after second vaccination ]

3.  Primary:   Number of Participants Reporting Measured Injection Site Reactions of Swelling and Redness After the First Vaccination   [ Time Frame: Day 0-7 after first vaccination ]

4.  Primary:   Number of Participants Reporting Measured Injection Site Reactions of Swelling and Redness After the Second Vaccination   [ Time Frame: Day 0-7 after second vaccination ]

5.  Primary:   Number of Participants Reporting Solicited Systemic Symptoms Based on the Functional Grading Scale After the First Vaccination   [ Time Frame: Day 0-7 after first vaccination ]

6.  Primary:   Number of Participants Reporting Solicited Systemic Symptoms Based on the Functional Grading Scale After the Second Vaccination   [ Time Frame: Day 0-7 after second vaccination ]

7.  Primary:   Number of Participants Reporting Fever After the First Vaccination   [ Time Frame: Day 0-7 after first vaccination ]

8.  Primary:   Number of Participants Reporting Fever After the Second Vaccination   [ Time Frame: Day 0-7 after second vaccination ]

9.  Primary:   Number of Participants in the 18-64 Year Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Prior to and 8-10 Days Following 1 Dose of H1N1 Vaccine   [ Time Frame: Day 0 prior to and Day 8-10 after first vaccination ]

10.  Primary:   Number of Participants in the 65 Years and Older Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Prior to and 8-10 Days Following 1 Dose of H1N1 Vaccine   [ Time Frame: Day 0 prior to and Day 8-10 after first vaccination ]

11.  Primary:   Number of Participants in the 18-64 Year Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of H1N1 Vaccine   [ Time Frame: Day 21 after first vaccination ]

12.  Primary:   Number of Participants in the 65 Years and Older Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of H1N1 Vaccine   [ Time Frame: Day 21 after first vaccination ]

13.  Primary:   Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs)   [ Time Frame: Day 0 through Day 180 after last vaccination ]

14.  Primary:   Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 1 Dose of Vaccine   [ Time Frame: Day 0 prior to and Day 8-10 after first vaccination ]

15.  Primary:   Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 1 Dose of Vaccine   [ Time Frame: Day 0 prior to and Day 8-10 after first vaccination ]

16.  Primary:   Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of Vaccine   [ Time Frame: Day 0 prior to and Day 21 after first vaccination ]

17.  Primary:   Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of Vaccine   [ Time Frame: Day 0 prior to and Day 21 after first vaccination ]

18.  Secondary:   Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 0 prior to first vaccination and Day 8-10 after the second vaccination ]

19.  Secondary:   Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 0 prior to first vaccination and Day 8-10 after the second vaccination ]

20.  Secondary:   Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 0 prior to first vaccination and Day 21 after the second vaccination ]

21.  Secondary:   Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 0 prior to first vaccination and Day 21 after the second vaccination ]

22.  Secondary:   Number of Participants in the 18-64 Year Age Stratum With a Serum HAI Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 8-10 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 8-10 after the second vaccination ]

23.  Secondary:   Number of Participants in the 65 Years and Older Age Stratum With a Serum HAI Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 8-10 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 8-10 after the second vaccination ]

24.  Secondary:   Number of Participants in the 18-64 Year Age Stratum With a Serum HAI Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 21 after the second vaccination ]

25.  Secondary:   Number of Participants in the 65 Years and Older Age Stratum With a Serum HAI Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 2 Doses of H1N1 Vaccine.   [ Time Frame: Day 21 after the second vaccination ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Solicited events were collected for 8 days after each vaccination, unsolicited events through 21 days after last vaccination, and serious adverse events and new onset chronic medical conditions through 180 days after last vaccination.
Additional Description For events solicited on a Memory Aid in the 8 days after vaccination, a participant was considered to have one event if it was reported as experienced at any time in the 8 day period.

Reporting Groups
  Description
H1N1 Vaccine 15 Mcg Participants received 15 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.
H1N1 Vaccine 30 Mcg Participants received 30 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.

Serious Adverse Events
    H1N1 Vaccine 15 Mcg   H1N1 Vaccine 30 Mcg
Total, Serious Adverse Events     
# participants affected / at risk   7/204 (3.43%)   7/204 (3.43%) 
Cardiac disorders     
Atrial fibrillation * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Gastrointestinal disorders     
Vomiting * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
General disorders     
Chest discomfort * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Chest pain * 1     
# participants affected / at risk   2/204 (0.98%)   0/204 (0.00%) 
# events   2   0 
Infections and infestations     
Cellullitis * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Pneumonia * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Injury, poisoning and procedural complications     
Multiple injuries * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Subdural haematoma * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
Mycosis fungoides * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
Nervous system disorders     
Loss of consciousness * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
Transient ischaemic attack * 1     
# participants affected / at risk   2/204 (0.98%)   0/204 (0.00%) 
# events   2   0 
Cerebral haemorrhage * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
Syncope * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
Reproductive system and breast disorders     
Breast mass * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
Surgical and medical procedures     
Cholecystectomy * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
Surgery * 1     
# participants affected / at risk   0/204 (0.00%)   1/204 (0.49%) 
# events   0   1 
Vascular disorders     
Aortic stenosis * 1     
# participants affected / at risk   1/204 (0.49%)   0/204 (0.00%) 
# events   1   0 
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA (13.0)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Patricia Winokur, MD
Organization: Carver College of Medicine, University of Iowa
phone: 319-384-1735
e-mail: patricia-winokur@uiowa.edu


Publications of Results:

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00943488     History of Changes
Other Study ID Numbers: 09-0043
N01AI80008C
First Submitted: July 21, 2009
First Posted: July 22, 2009
Results First Submitted: March 10, 2011
Results First Posted: April 11, 2011
Last Update Posted: October 31, 2012